prikaz prve stranice dokumenta Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
  Download
PDF 992.36 KB
Scientific paper - Original scientific paper
Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
American Journal of Cardiology, 113 (2014), 10; 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024
Gašparović, Hrvoje; Petričević, Mate; Kopjar, Tomislav; Đurić, Željko; Svetina, Lucija; Biočina, Bojan

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Gašparović, H., Petričević, M., Kopjar, T., Đurić, Ž., Svetina, L. & Biočina, B. (2014). Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology, 113. (10), 1660-1667. doi: 10.1016/j.amjcard.2014.02.024

Gašparović, Hrvoje, et al. "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting." American Journal of Cardiology, vol. 113, no. 10, 2014, pp. 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024

Gašparović, Hrvoje, Mate Petričević, Tomislav Kopjar, Željko Đurić, Lucija Svetina and Bojan Biočina. "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting." American Journal of Cardiology 113, no. 10 (2014): 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024

Gašparović, H., et al. (2014) 'Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting', American Journal of Cardiology, 113(10), pp. 1660-1667. doi: 10.1016/j.amjcard.2014.02.024

Gašparović H, Petričević M, Kopjar T, Đurić Ž, Svetina L, Biočina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology [Internet]. 2014 May 15 [cited 2024 May 01];113(10):1660-1667. doi: 10.1016/j.amjcard.2014.02.024

H. Gašparović, M. Petričević, T. Kopjar, Ž. Đurić, L. Svetina and B. Biočina, "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting", American Journal of Cardiology, vol. 113, no. 10, pp. 1660-1667, May 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:020711. [Accessed: 01 May 2024]

Metadata
Title (english)Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
AuthorHrvoje Gašparović
AuthorMate Petričević
AuthorTomislav Kopjar
AuthorŽeljko Đurić
AuthorLucija Svetina
AuthorBojan Biočina
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery disease. Interpatient variability to antiplatelet agents, however, harbors the potential to compromise the revascularization benefit by increasing the incidence of adverse events. This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients randomized to aspirin-monotherapy (relative risk 0.61, 95% confidence interval 0.25 to 1.51, p = 0.33). No significant treatment effect was noted in the occurrence of the safety end point. The total incidence of bleeding events was 25% and 19% in the dAPT and aspirin-monotherapy groups, respectively (relative risk 1.34, 95% confidence interval 0.80 to 2.23, p = 0.33). In the subgroup analysis, dAPT led to lower rates of adverse events in patients with a body mass index >30 kg/m(2) (0% vs 18%, p <0.01) and those <65 years (0% vs 10%, p = 0.02). In conclusion, the addition of clopidogrel in patients found to be aspirin resistant after coronary artery bypass grafting did not reduce the incidence of adverse events, nor did it increase the number of recorded bleeding events. dAPT did, however, lower the incidence of the primary end point in obese patients and those <65 years.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleAmerican Journal of Cardiology
Numberingvol. 113, no. 10, pp. 1660-1667
p-ISSN0002-9149
DOIhttps://doi.org/10.1016/j.amjcard.2014.02.024
URN:NBNurn:nbn:hr:105:020711
Publication2014-05-15
Document URLhttps://doi.org/10.1016/j.amjcard.2014.02.024
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 20:16:20